Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-
related lung cancers continue to account for the majority of diagnoses, smoking rates have …

Lung cancer has been the most common and the leading cause of cancer deaths globally.
Besides clinicopathological observations and traditional molecular tests, the advent of …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC …

Abstract Background About 10% of NSCLCs are mutated in KRAS and impaired in
STK11/LKB1, a genetic background associated with poor prognosis, caused by an increase …

Background and Objective: This review comprehensively explores the intricate landscape of
anaplastic lymphoma kinase (ALK), focusing specifically on its pivotal role in non-small cell …

Despite the tremendous progress in cancer treatment in recent decades, cancers often
become resistant due to multiple mechanisms, such as intrinsic or acquired multidrug …

Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell
lung cancer (NSCLC) constitutes around 85% of all lung cancer cases. Recently, the …

Per-and polyfluoroalkyl substances (PFASs) have potential carcinogenicity, immunotoxicity,
and hepatotoxicity. Research has been conducted on PFAS exposure in people to discuss …

Introduction The emergence of anaplastic lymphoma kinase (ALK) rearrangements in non-
small cell lung cancer (NSCLC) has revolutionized targeted therapy. This dynamic …

Introduction Nearly 60% of patients with non-small cell lung cancer (NSCLC) present with
metastatic disease, and approximately 20% have brain metastases (BrMs) at diagnosis …